Medication use in PH patients requires careful selection and continuation of therapies to maintain hemodynamic stability and pulmonary vasodilation. Proper pharmacologic management can significantly reduce perioperative complications and optimize outcomes.
Vasodilators
Pulmonary vasodilators, such as inhaled nitric oxide or prostacyclins, mentioned in Hemodynamic Management, play a critical role in managing PVR. These agents improve oxygenation and reduce pulmonary artery pressures, enhancing hemodynamic stability.
Anticoagulants
Anticoagulants are commonly used in patients with PH, particularly those with chronic thromboembolic pulmonary hypertension (CTEPH). Careful perioperative management is essential to balance the risks of bleeding and thrombosis. Collaboration with hematologists or the patient’s pulmonologist is often necessary to adjust the dosage and timing of anticoagulation therapy, particularly during surgery when bleeding risks are heightened.
Anesthetic Agents
Agents like etomidate are preferred for induction due to their minimal cardiovascular effects. Opioids such as fentanyl or remifentanil are commonly used to maintain hemodynamic stability during surgery. The choice of anesthetic should prioritize minimizing myocardial depression and systemic vasodilation. Ketamine, with its minimal effect on systemic blood pressure and ability to preserve sympathetic tone, may also be considered in select cases. The perioperative team must ensure that anesthetic agents do not exacerbate pulmonary vasoconstriction or impair right ventricular function.
Pulmonary Vascular Resistance Management: To avoid increased pulmonary vascular resistance (PVR), maintain adequate oxygenation and normocapnia and prevent acidosis. If needed, consider inhaled nitric oxide or prostacyclin analogs to dilate pulmonary vasculature selectively.
Postoperative Care: Monitor the patient in an ICU with continuous cardiac monitoring. Manage pain effectively to prevent sympathetic stimulation and balance fluids to avoid volume overload and hypovolemia, protecting right ventricular function.
| Agent | Role | Key consideration |
|---|---|---|
| Etomidate | Preferred induction agent. | Minimal cardiovascular effects. |
| Ketamine | Alternative induction agent in select cases. | Minimal effect on systemic blood pressure and preserves sympathetic tone. |
| Fentanyl or remifentanil | Maintenance of hemodynamic stability during surgery. | — |
| Inhaled nitric oxide | Selective pulmonary vasodilation to control pulmonary vascular resistance. | Reduces pulmonary artery pressures and improves oxygenation without compromising systemic blood pressure. |
| Prostacyclins | Selective pulmonary vasodilation. | Improve oxygenation and reduce pulmonary artery pressures, enhancing hemodynamic stability. |
| Phosphodiesterase inhibitors (sildenafil, tadalafil) and endothelin receptor antagonists (bosentan) | Chronic PH-specific therapy. | Continue perioperatively; review the regimen preoperatively with the pulmonologist or cardiologist. |
| Anticoagulants | Commonly used, particularly in chronic thromboembolic pulmonary hypertension. | Balance bleeding against thrombotic risk; collaborate with hematology or pulmonology on dose and timing around surgery. |
| Dobutamine | Inotropic support of right ventricular function and cardiac output. | Considered postoperatively and when right ventricular failure is recognized. |
| Norepinephrine | Vasopressor support of systemic blood pressure. | Used alongside PH-specific therapy to support right ventricular function postoperatively. |
